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Abstract
In carcinomas stromal cells participate in cancer progression by producing proteases such as MMPs. The expression MMP1 is
a prognostic factor in human chondrosarcoma, however the role in tumor progression is unknown. Laser capture
microdissection and In Situ hybridization were used to determine cellular origin of MMP1 in human sarcomas. A xenogenic
model of tumor progression was then used and mice were divided in two groups: each harboring either the control or a
stably MMP1 silenced cell line. Animals were sacrificed; the neovascularization, primary tumor volumes, and metastatic
burden were assessed. LCM and RNA-ISH analysis revealed MMP1 expression was predominantly localized to the tumor cells
in all samples of sarcoma (p=0.05). The percentage lung metastatic volume at 5 weeks (p=0.08) and number of
spontaneous deaths secondary to systemic tumor burden were lower in MMP1 silenced cell bearing mice. Interestingly, this
group also demonstrated a larger primary tumor size (p,0.04) and increased angiogenesis (p,0.01). These findings were
found to be consistent when experiment was repeated using a second independent MMP1 silencing sequence. Prior clinical
trials employing MMP1 inhibitors failed because of a poor understanding of the role of MMPs in tumor progression. The
current findings indicating tumor cell production of MMP1 by sarcoma cells is novel and highlights the fundamental
differences in MMP biology between carcinomas and sarcomas. The results also emphasize the complex roles of MMP in
tumor progression of sarcomas. Not only does metastasis seem to be affected by MMP1 silencing, but also local tumor
growth and angiogenesis are affected inversely.
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Introduction
The process of sarcoma metastasis is an event in which
mesenchymal tumor cells escape confines of local disease control
measures and threaten the life of the host. The metastatic process
thus is a very attractive target for novel therapies but a
fundamental understanding of the process is necessary to design
effective therapies. The mechanisms underlying the metastatic
cascade of sarcomas are largely unknown and may differ
significantly from that of carcinomas in which there is a
preliminary understanding. Many cellular and molecular elements
of the tumor microenvironment have emerged as attractive targets
for therapeutic strategies among carcinomas. One such putative
target, metalloproteinases, have been implicated in many processes
involved in tumor progression including anti-angiogenic therapies
[1].
Although MMPs have been implicated in a variety of diseases
such as arthritis, atherosclerosis etc., it was evidence of their role in
cancer progression that lead to attempts at therapeutic application
[2]. Several broad spectrum synthetic MMP inhibitors were put
into clinical trials; results of which have largely been disappointing
[3]. There have been numerous studies presenting conflicting
evidence of a pro-tumorigenic versus protective roles of various
MMPs [4,5]. This highlights the need for an improved
understanding of specific roles for different MMPs in tumor
progression that can lead to a more targeted and hopefully
successful therapy in future.
Most of the in vitro/in vivo studies and clinical trials exploring
MMP inhibition in cancer were on carcinomas which are
malignancies of epithelial origin. In these malignancies, the
development of a tumor requires support from the surrounding
host stromal tissue, also referred to as the tumor microenviron-
ment [6]. Carcinoma-associated fibroblasts, leukocytes, bone
marrow-derived cells, blood and lymphatic vascular endothelial
cells present within the tumor microenvironment contribute to
tumor progression [7]. The dynamic and reciprocal interactions
between tumor and host cells orchestrate events critical to tumor
progression. Tumor cells have been shown to induce MMP
production in surrounding stromal and inflammatory cells of
mesenchymal origin such as fibroblasts, macrophages and mast
cells. Numerous studies utilizing RNA in situ hybridization to
evaluate MMP expression in human tumor tissue revealed that
most MMPs are predominantly expressed by stromal cells which
are of mesenchymal origin [8]. These studies were performed on
carcinomas arising in organs such as lung, breast, head and neck,
prostate, bladder, and colon [9]. Recently, Gupta et al. have
reported MMP1 as a member of lung metastatic gene signature
(LMS) for breast carcinoma [10]. They also proposed sub-
categorizing the genes involved in metastasis and recognized
MMP1 as a metastatic progression gene: a gene that has dual
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e14250functions in mediating primary tumorigenesis and metastatic
colonization, for a specific breast cancer cell-line model [11].
In malignancies of mesenchymal origin, little is known about the
role of MMPs in tumor progression. Previously, we reported the
prognostic significance of MMP1 gene expression in patients with
chondrosarcoma [12]. Subsequent studies demonstrated the
correlation of MMP1 silencing by antisense oligonucleotides and
shRNA with reduced invasive potential of sarcoma cells in vitro
[13,14,15,16,17,18]. We hypothesize that the majority of MMP
production can be attributed to tumor cells in sarcomas in contrast
to mesenchymal stromal cells in carcinomas. Determining this
difference is critical if inhibition of MMP activity is to be
entertained as a potential antitumor therapy in these tumors.
Based on our earlier in vitro findings we hypothesized that the
effects of stable MMP1 silencing would lead to decreased
metastasis in vivo. In order to determine the target cell population
for MMP1 silencing, we carried out an expressional analysis of
MMP1 in human chondrosarcoma specimens by both laser
capture microdissection and in situ hybridization. These two
complementary lines of evidence indicate that sarcoma cells serve
as the primary source of MMP1 in this tumor. Subsequently, the
potential of MMP1 as a therapeutic target in human sarcoma was
tested in an orthotopic xenogenic model using shRNA technique
to stably silence MMP1 in human sarcoma cells. The results
demonstrate that MMP1 silencing was associated with a trend of
decreased rate of pulmonary metastasis but also increases in
primary tumor volume and vascularization. Whether these
represent direct effects by decreasing pericellular collagen
degradation or indirect effects will require further study [19].
Results
Cellular Origin of MMP1 in human sarcoma samples
The cellular origin of human chondrosarcoma was evaluated in
sections of surgical isolates using both laser capture microdissec-
tion and in situ hybridization. Quantitative RT- PCR was used to
quantitate the MMP1 mRNA in human chondrosarcoma cells and
in adjacent stromal cells following isolation by laser capture
microdissection (Figure 1; Panel A). Each cell population was
collected and processed separately and MMP1 gene expression
analysis was performed using the ABI Taqman gene expression
assays. Concurrent analysis of TIMP1 gene expression, the
naturally occurring inhibitor for MMP1, and two housekeeping
genes: a structural gene, 18S, and an expressional gene, B2M,
were performed for quality assurance and normalization of gene
expression [20]. The level of gene expression for each sequence
from both host and tumor cell populations are shown in table 1.
MMP1 gene expression was detectable largely in the tumor cell
population (p=0.05). The range of difference in expression of
MMP1 between tumor cells and stromal cells after normalization
ranged from 4 -fold to a 100-fold difference. There was minimal
MMP1 gene expression detected in host stromal cells. The control
genes (including TIMP1 and the two housekeeping genes)
demonstrated comparable expression in tumor and stromal cells
for each sample indicating mRNA recovery and quantitation were
similar in tumor and stromal cells (Table 1). This corroborates
previous studies and that the observed difference in expression of
MMP1 between host and tumor cells is genuine; and the
populations of cells collected for analysis from the tumor and
stromal aspects of the tumor were comparable.
Messenger RNA In-Situ Hybridization (ISH) was used as an
independent means of ascertaining the cellular origin of MMP1
gene expression in human sarcoma tissue. Corresponding
photomicrographs for each tumor sample are shown in (Figure 1;
Panel B). In-situ hybridization with an anti-sense probe demon-
strates that MMP1 gene expression is detectable only in tumor
cells and not in surrounding host stromal cells. A sense probe was
used as a control in parallel sections under the same hybridization
conditions. These did not reveal any staining in the tumor or in the
stromal part for all three samples indicating the specificity of the
hybridization. This result was consistent for all three human
chondrosarcoma samples.
MMP1 Silencing of Human Sarcoma cells
To determine the involvement of MMP1 in chondrosarcoma
metastasis,MMP1geneexpressionwasstablysilencedusingshRNA
approach. QPCR was used to determine the relative quantities of
MMP1 gene expression in the two stably shRNA transfected clones
and are displayed in Figure 2A. There was a 98% reduction of
MMP1 gene expression of in silenced cells when compared with the
controlcells (scrambled shRNA sequence). Western blotting verified
that the MMP1 gene expression silencing resulted in a reduced
protein level (Figure 2B). There were no significant changes in gene
expression of other collagenases, specifically MMP8 and MMP13
indicating that the shRNA silencing was specific for MMP1. We
repeated our experiment to confirm our findings using a second
shRNA sequence: T6-7. When compared to scrambled sequence,
there was a 70% (as opposed to 96%) reduction of MMP1 gene
expression (data not shown).
In Vitro Cell Proliferation and Invasion
In an attempt to determine the effect of MMP1 gene expression
silencing in vitro on cell proliferation and invasion, assays of these
parameters in control and silenced cell clones were determined,
Figure 2 C and D. The difference in mean proliferation of the two
clones over 5 days was not statistically significant (p=0.80).A Boyden
chamberemployingatype1collagensurfacewasusedtoassessinvitro
invasion over 48 hrs. Control cells were determined to be 2.666
more invasive than MMP1 silenced cells, p,0.001 (Figure 2D).
Primary Tumor Growth
The effect of MMP1 gene expression silencing was then
evaluated in vivo in a xenogenic model of metastasis. Primary
tumor volume was assessed in tumor bearing mice (n=70) at 2, 4
and 5 weeks (figure 3A). A graphical representation of mean tumor
volume (mm
3) for a single mouse over time and the differences
among the two groups of mice bearing control and silenced clones
of 143B cell-line are depicted (Figure 3B). Tumors were visibly
larger in mice bearing the MMP1 silenced clone and continued to
show increased growth over time as depicted in the histogram.
The differences in the mean tumor volume in two groups were
statistically significant at 2, 4, and 5 weeks, (p,.04) (con-
trol=349679; MMP1=9006180 mm
3 2 wks, control =
35686277; MMP1=46906404 mm
3 4 wks, and control =
56366615; MMP1=78916716 mm
3 5 wks respectively). Further
analysis revealed that MMP1 silenced group had a constant rate of
tumor growth over 5 weeks whereas mice bearing control group
showed a plateau in tumor growth over time. There was no
difference in survival between mice with control and MMP1
silenced tumor clones. The experiment was repeated using the T6-
7 clone and the primary tumor growth followed similar trends.
Mice bearing T6-7 clone grew bigger tumors at 2 and 5 weeks
(p,0.05) (supplementary Table S1).
Primary Tumor Vascularity
In an attempt to understand the effects of MMP1 gene silencing
on primary tumor growth, tumor vascularity was assessed. Tumor
MMP1 in Sarcomas
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with confocal microscopy. Photomicrographs from the two groups
of mice are shown in Figure 4. The primary tumor in the control
group consisting of GFP labeled sarcoma cells and Di-I stained red
blood vessels are depicted in Figure 3A. The image demonstrates
new tumor associated vessels. Corresponding images from MMP1
silenced group of mice are depicted in Figure 4B. Distinct
neoangiogenic sprouts can be appreciated and highlighted in the
supplemental video S1, corresponding to Figure 4B. In figure 4C
& D, the vascularity of the tumors is measured by isolation of red
fluorescence signal intensity for both the control and silenced cells.
The tumor containing MMP1 silenced cells demonstrates
increased vascularity and increased number small vessels ap-
proaching the tumor cells.
Analysis of vascularity revealed a statistically significant increase in
mean vascular volume per unit volume of tumor for MMP1 silenced
group (321233641140 threshold pixels) as compared to control
(184283678021 threshold pixels) group (p=0.01) (Figure 4E). This
trend was consistent when the experiment was performed again using
T6-7 clone. The mean vascularity for T-67 clone was almost twice as
high as for control clone (supplemental Table S1).
Pulmonary Burden
The effect of MMP1 silencing on metastasis was determined
following necropsy at five weeks when the lungs were isolated.
Figure 5 shows a digital photograph of two pairs of lungs from A)
control and B) MMP1 silenced groups clearly showing areas of
gross metastasis. An estimation of percentage of total lung volume
affected by metastasis revealed a higher percentage of volume
affected in control group (54%62.20) as compared to MMP1
silenced group (36%62), p=0.08. This information is graphically
depicted in Figure 5C. Once again, this trend is also consistent
with T-67 clone although the difference was further reduced
between T-67 and control as shown in the supplementary file.
Characterization of Isolated sarcoma cells from mice
Stability of MMP1 over time was assessed by examining gene
expression post necropsy in pulmonary metastasis. Figure 6A
Figure 1. Cellular Origin of MMP1. Figure 1 A: Laser Capture Micro-dissection pictures at 206magnification for CS1488, CS 114 and OBT-0001,
Figure 1 B: In-situ RNA Hybridization results for CS 1488, CS 114 and OBT-0001. Black staining reveals the MMP expression in the tissue. The stained
part in figure 1b with vacuolization represents the tumor cells and the unstained fibrous part represents the stromal cells.
doi:10.1371/journal.pone.0014250.g001
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from the control group and the silenced group. The relative level
of MMP1 expression in control and silenced isolated cells (97%
down) was similar to the original extent of MMP1 silencing prior
to implantation indicating stability of the shRNA effect through
the in vivo tumor growth and metastasis. Furthermore, peri-
tumoral MMP1a & MMP1b production by murine stromal tissue
was assessed with laser capture microdissection and QPCR,
figure 6B. Murine stromal cells in both control and silenced cells
did not produce murine MMP1 at detectable levels. Murine MMP
13 contribution was also negligible (data not shown). Hence
MMP1 was present only in human tumor cells without an induced
contribution from the surrounding murine cells.
Lack of murine tissue positive for MMP1a, MMP1b and
MMP13 in the vicinity of tumor limited us to include a positive
control for the above mentioned experiment. However, the proper
functioning of murine primers was established in other experi-
ments carried out on a murine breast cancer cell line.
Discussion
Prior to 1990, most findings regarding MMP1 expression were
derived from analysis of cell lines and a few immunohistochemical
studies of human tumors [21]. These results were consistent with
the concept that MMPs proteins were mainly expressed by cancer
cells. However, in situ localization studies to evaluate MMP gene
expression directly in human cancer specimens dramatically
modified this concept [22]. A majority of studies determining
the origin of MMPs in carcinomas were based only on in situ
mRNA hybridization techniques [23,24]. Indeed, most MMPs
were found to be predominantly expressed by stromal cells of
mesenchymal origin in human carcinomas, but not in the cancer
cells of epithelial origin [25]. This was regarded as a fundamental
change in the MMP biology in a neoplastic microenvironment of
carcinomas and questioned the validity of MMP silencing in
studies of carcinoma metastasis [25].
The majority of human malignancies are of epithelial origin (i.e.
carcinomas) and thus little, if any, attention has been given to the
origin of MMPs in malignancies of mesenchymal origin (i.e.
sarcomas). However, many sentinel discoveries of tumor biology
have arisen from studies of these tumors [26]. The current report
is the first in-depth analysis of role of MMP1 in sarcoma biology.
The study of the microenvironment of sarcomas reveals an
interesting situation where cancer cells of mesenchymal origin are
surrounded by stromal cells of the same origin. Understanding the
relationship of host and tumor cells in mesenchymal malignancies
is likely to provide new insights into tumor progression that may be
of broader applicability beyond this group of infrequent
malignancies.
Earlier results from our laboratory indicate a prognostic
significance of MMP1 expression in disease specific survival of
patients with chondrosarcoma [12]. The current study extends the
understandingofthe role ofMMP1insarcoma biologybylocalizing
the synthesis to tumor cells. Two complementary and independent
approaches were used in the current study to address this question.
Laser capture microdissection has been a very sensitive technique to
distinguish tumor and stromal gene expression for a number of
malignancies including breast, prostate, pancreatic, colon and
gastric cancers [27,28]. Similarly mRNA-ISH technique has been
used to determine gene expression in a number of tumors including
giant cell tumors of bone [29]. Interestingly, both experimental
approaches indicate that MMP1 is primarily expressed in human
sarcoma cells as and not the surrounding stromal cells. This result is
in sharp contrast to what has been reported in the literature for
carcinomas [28]. Furthermore in the examination of xenogenic
metastasis wheremurine and human MMP1canbe distinguished, it
is clear that sarcomas do not induce MMP1 expression in
surrounding stromal tissue.
This finding has several implications on both experimental, as
well as therapeutic aspects. MMPs have been widely implicated as
a therapeutic target for antitumor therapy [10]. Xenogenic models
have been primarily used to delineate the role of MMPs in tumor
carcinoma progression. RNA interference techniques to silence
MMPs have been used in numerous carcinoma cell lines and a
melanoma cell line [10,30]. These cell lines were subsequently
injected in animals to investigate the role of MMP1 silencing on
tumor progression. These models have an inherent flaw because
Table 1. Results of QPCR Analysis for CS 1488, CS 114 and OBT-0001.
Sample 18S TIMP1 MMP1 B2M MMP1:18S
CS 1148
Tumor 4.41E-05 9.06E-08 1.96E-06 1.88E-07 4.44E-02
Tumor 9.07E-05 1.35E-07 6.03E-06 2.31E-07 6.65E-02
Stromal 8.75E-04 3.84E-07 4.22E-07 6.54E-06 4.82E-04
Stromal 3.76E-05 4.64E-07 3.19E-07 2.05E-05 8.48E-03
CS 114
Tumor 5.41E-03 3.84E-06 2.10E-06 1.35E-05 3.88E-04
Tumor 9.06E-04 1.02E-06 4.79E-07 2.17E-06 5.29E-04
Stromal 1.60E-03 8.09E-07 1.73E-07 2.28E-06 1.08E-04
Stromal 1.50E-03 8.97E-07 2.15E-07 2.96E-07 1.43E-04
OBT-0001
Tumor 3.58E-05 1.77E-07 6.27E-07 2.97E-07 1.75E-02
Tumor 1.11E-04 3.00E-07 1.96E-07 2.26E-07 1.77E-03
Stromal 4.32E-05 2.00E-07 4.28E-08 2.06E-07 9.91E-04
Stromal 3.21E-05 1.90E-07 Undetermined 2.01E-07 Undetermined
doi:10.1371/journal.pone.0014250.t001
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cells which remain MMP1 competent after tumor cell silencing.
Our finding encouraged us to investigate the role of MMP1 in a
xenogenic sarcoma model that appears to be more appropriate
model for investigation of the role of MMPs in tumor biology, as
there is minimal contribution of MMPs from stromal cells.
The current study is unique and comprehensive for determining
the cellular origin of MMP1 in sarcoma samples, carrying out the
stable silencing of target cells and following disease progression in
a xenogenic murine model of sarcoma. It demonstrates that
MMP1 silencing results in increased local tumor growth and
increased vascularity of the primary tumor but less systemic
disease burden in a xenogenic murine model of human sarcoma.
This is the first report of localized pro-tumorigenic effects of
MMP1 silencing and more importantly the first report of opposing
effects on local growth versus systemic tumor burden of MMP1 in
an animal model of metastasis.
Martin and Matrisian recently reviewed protective roles of
MMPs in tumor progression [5]. MMP3 has been shown to
decrease initial growth rates of squamous cell carcinoma in wild
type mice compared to knockouts [31]. Another study reported
decreased development of mammary tumors in transgenic mice
expressing MMP3 [32]. MMP12 expression has been implicated
in increased number of well-differentiated tumors with better
outcomes [33]. Another collagenase, MMP8 when silenced
resulted in decreased latency period and increased number of
papillomas [34].
Role of MMP1 has been well documented in the establishment
of lung metastasis in breast cancer [35] as well for establishment of
primary lung cancer [36]. Gupta et al. suggested a role of MMP1
in vascular remodeling co-opted for sequential steps in lung
metastasis [10]. Current results support these findings and provide
evidence for a pro-metastatic role of MMP1 in a xenogenic murine
model of human sarcoma. Higher rates of pulmonary tumor
burden in control group resulted in a higher incidence of
spontaneous deaths. Opposing effects on local tumor growth and
systemic tumor burden have historically been reported for
stromelysin-3 (MMP11) [37]. The difference in pulmonary tumor
burden and survival in two groups of mice in the current study are
not statistically significant. It is very important to interpret these
results recognizing that 1) mice dying spontaneously (control=6;
silenced=2) could not be assessed for pulmonary burden of
Figure 2. Results of MMP1 Silencing. Figure 2A) Relative quantity (RQ) of MMP1 in the stable clones of 143B cell-line prepared. MMP1 Silenced is
98% down-regulated as compared to control. Control =1.0060.13; MMP1 Silenced=0.1860.14. Figure 2B) displays the Western Blot analysis for
MMP1 production by the stable clones of 143B cell-line. MMP1 Silenced clone shows down-regulation at the level of protein as compared to control.
Figure 2C) displays in vitro proliferation assay showing growth of control and MMP1 silenced clones over 5 days. There is an approximately 14%
increased growth displayed by MMP1 silenced clone in the log-phase of growth. Difference in mean growth over 5 days is statistically insignificant
(p=0.804). Figure 2D) displays results for the in vitro invasion assay measured in Relative Light Units (RLU). Control=21272.76790; MMP1
silenced=8008.16874.5 RLUs (p=1.54E-09).
doi:10.1371/journal.pone.0014250.g002
MMP1 in Sarcomas
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plan was truncated because of primary tumor burden being
greater than 10% body weight (5 weeks) than originally planned
(8-12 weeks) per IACUC stipulations. Mice dying spontaneously
had a higher systemic disease burden as compared to the rest of
the cohort. A higher number of spontaneous deaths negatively
skewed the pulmonary burden in control group as compared to
MMP1 silenced group. While the study was adequately powered
from the outset, this may represent a beta statistical error.
Patients with pancreatic and small-cell lung cancer showed
significantly poorer outcome with and MMP inhibitor therapy
leading to early termination of the trial [3]. Subsequently reports
have emerged over the past decade that challenged the dogma of
proteases being exclusively tumor promoting potentially explain-
ing these clinical results. Merchan et al. reported anti-angiogenic
and anti-proliferative effects mediated by uPA’s protease activity
[38]. The observation that MMP1 silencing is associated with
increased primary tumor volume is novel and is in contrast to what
has been observed in breast cancer where MMP1 silenced tumors
demonstrated reduced primary tumor size.[39] The possible
underlying mechanisms for increased primary tumor size in
sarcoma is unclear and may be secondary to an underlying
catabolism of anabolic factors or other mitogenic signaling
molecules by MMP1. An alternative mechanism could be
secondary to increased vascular perfusion [19].
Pro- and anti-angiogenic roles of different MMPs in tumor
angiogenesis have been well documented in literature [40]. MMP1
has been implicated in release of bFGF and VEGF from the
extracellular matrix to promote angiogenesis [41,42]. It has also
been implicated in targeting endothelial proteinase-activated
receptor 1 and thus activating endothelial cells [43]. Brinckerhoff
et al. recently showed that RNAi mediated inhibition of MMP1
lead to reduction of angiogenesis in murine models of melanoma
and breast cancer [4,30]. We herein report an increase in tumoral
angiogenesis as a result of MMP1 silencing. Several other MMPs
including MMP 2, 3, 7, 9, 12 have been shown to perform both
pro- and anti-angiogenic roles [40]. Mechanisms for anti-
angiogenic effects include cleavage of FGFR1 and uPAR, the
release and subsequent binding of PEX domain to avb3 on MMP
degradation, and formation of potent angiogenesis inhibitor
peptides. One of such peptides is endostatin, generated by
proteolytic cleavage of C-terminal of type XVIII collagen a1
chain. Another collagenase MMP13 has been implicated in its
production of endostatin [44]. Since MMP1 and MMP13 share
the same collagen cleavage point, it may be that MMP1 is
manifesting its anti-angiogenic effects through this mechanism.
The method described is a new method for visualizing the
vascularity in tumor bed. But we feel it is more accurate as
compared to traditional immune-histochemistry with CD 31 or
CD 34 antibodies. In this method, vascularity is assessed in three
dimensions in a 50 micron thick section and from each tumor 5
representative areas were imaged, ensuring adequate representa-
tion. Immunohistochemistry is limited to two dimensions only and
can be misleading especially when investigating a highly vascular
tumor bed since vessels can be running along the plane of section
or the same vessel can be crossing the plane of section at multiple
points, potentially giving a false assessment. Thus, we believe our
method, although new, provides a better assessment of vascularity.
We would also like to suggest a comparison of this method with the
traditional immunohistochemistry method in future.
This study highlights that there are fundamental differences in
terms of MMP biology between sarcomas and carcinomas. Not
only the cellular origin of MMP differs, but MMP1 silencing
affects the disease progression in xenogenic models in different
ways. In addition to the hypothesized pro-metastatic roles, the
current study also identified additional effects on vascularity and
primary tumor growth [11]. Repeating the experiment using a a
second shRNA sequence and subsequent MMP1 silenced tumor
Figure 3. Primary tumor size. Tumor volumes in ‘control’ and ‘MMP1 silenced’ groups at 5 week intervals are shown in Figure 3A. Figure 3B
displays the histograms showing mean volume of tumor (mm
3) for a single mouse in control and MMP1 silenced groups at corresponding time
points. Difference in tumor volumes at 2, 4 and 5 weeks is significant with p-values of 0.023, 0.036 and 0.026.
doi:10.1371/journal.pone.0014250.g003
MMP1 in Sarcomas
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result of clonal variation or artifact. A gene acting as metastasis
progression gene for a breast cancer model may act as a metastasis
initiation gene or a metastasis virulence gene for a sarcoma model.
There are several potential limitations of the current study
including limited mechanistic insight to these novel observations.
The precise cellular and molecular mechanisms of MMP1 silenced
cells leading to increase in local tumor growth; angiogenesis and a
lower pulmonary burden are currently being pursued.
Materials and Methods
Three human chondrosarcoma samples were obtained from the
tumor bank at the Sylvester Comprehensive Cancer Center
following Institutional Review Board (IRB) approval. Informed
written consent was taken from all the patients after detailed
written and verbal description of the contents of consent. This
procedure was reviewed and approved by the University of Miami
ethics committee for research.
Laser Capture Microdissection
A laser capture microdissection technique was used to separate
the tumor cells and the surrounding stroma. A 5 micron
cryosection in OCT was obtained using Leica
R digital cryostat
at -20uC and sections were mounted on Director
R slides that
employ unique Laser Induced Forward Transfer (LIFT), a non-
contact microdissection technology. Approximately 500 cells were
collected per sample. LCM Hisogene
R Arcturus
R kit was used to
stain and dehydrate the sections and mRNA isolation was carried
out using an Arcturus
R Pico-pure
R RNA Isolation kit. RT reaction
was carried out using ABI oligo-dT probes (ABI Taqman Gene
Expression Assays
R Mm473485_m1) and QPCR was carried out
using ABI Real time Fast QPCR. Gene expression levels for 18S,
TIMP1, MMP1 and B2M were investigated for each sample. For
each tumor sample, 2 different populations of tumor and stromal
cells were microscopically dissected (Figure 1). Quantitative PCR
was performed on each of the tumor and stromal cell populations
collected for all three chondrosarcoma samples (Table 1). Five
different samples of tumor and stromal cells were dissected from
the entire section for each sample corresponding to a tumor and a
stromal sample in Table 1 for each of three chondrosarcoma
samples. A Paired Student t-test was used to compare the mean of
MMP1:18S for tumor and stromal cell populations.
Messenger RNA FISH
In situ hybridization using a DIG –labeled RNA probe for
human MMP1 (Exiqon) was performed as described [45]. Briefly,
a total of 17 nM of DIG-labeled probe was diluted into 100 mlo f
hybridization buffer, applied to the slides and allowed to hybridize
at 70uC overnight. Slides were then washed for 1 h at 70uCi n
0.26 SSC solution (Ambion-Applied Biosystems, CA) and
incubated with alkaline phosphatase-conjugated sheep anti-DIG
Figure 4. Primary tumor Vascularity. Confocal Images showing primary tumor from a) control group and b) MMP1 Silenced group. Images c) and
d) display only the blood vessels from a) and b). Figure 4E shows histograms representing average vascular volume (number of red pixels) for a single
field of vision (at 256) in tumors harbored by control (183829.7678022) and MMP1 Silenced (323147.5641141) groups. Difference in mean vascular
volume is significant with p-value=0.01.
doi:10.1371/journal.pone.0014250.g004
MMP1 in Sarcomas
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reaction was carried out in PVA with 200 ml of MgCl2 1 M and
140 ml of NBT/BCIP stock (Roche). Sense strand probe (Exiqon)
was used as a negative control.
Cell Culture and Reagents
The 143B sarcoma cell line was purchased from ATCC and
cells were grown in Dulbecco’s modified Eagle’s medium (DMEM
Invitrogen #10-0117CV) containing 10% fetal bovine serum
(FBS) and antibiotics in incubator set to 37uC with 5% CO2.
Preparation of 143B Stable Clones
The stable clones were generated by pHuSH 29mer shRNA
constructs against MMP1 (#TR311450 RNAi targeting vector
system OriGene Rockville, MD) as described [46]. We were
provided with four different sh RNA sequences and we used two
different sequences to generate T6-4 and its respective control
clone and the second independent clone T6-7 and its respective
control. Briefly, clones selected by puromycin (Invitrogen, 1.0 mg/
ml). Individual colonies were isolated and expanded in selection
media containing the antibiotics until passage was transferred into
p100 plates. Then clones cultured further for two passages and
screened for gene expression changes by QPCR. The screening
process was repeated multiple times to test expressional stability.
After verification of stable expression profiles, a control line (V9)
and an MMP1 RNAi silenced clone (T6-4) were selected. These
clones were further transformed with pEGFP-N1 fluorescent
reporter construct with FuGENE HD (# 04709705001, Roche
Corp.) to aid their identification (Clontech Laboratories Inc.
#6077-1 Mountain View, CA). Expressional profiles were tested
again to verify any changes in MMP1 RNAi down-regulation
levels, and then the established lines were stored frozen. The
expression of MMP1 mRNA relative to control was 0.01660.123.
The second independent clone T6-7 and its respective control
clone were generated using the same protocol, but a different
sequence of sh RNA supplied by OriGene Rockville, MD.
RNA Purification and Relative PCR
Total RNA was extracted from by using the RNeasy Mini kit
(Qiagen Corp. US #74104) according to the manufacturer
protocol. RT reaction was generated (Applied Biosystems #
4368813) and relative PCR was performed (Applied Biosystems
Taqman
R Gene Expression Assay Hs00233958_m1). The data
was then analyzed by DDCt method with the supplied software,
and according to the manufacturer’s protocol.
Western Blotting and Image acquisition
Cells were lysed in RIPA buffer (150 mM NaCl, 1.0%
IGEPALH CA-630, 0.5% sodium deoxycholate, 0.1% SDS,
50 mM Tris, pH 8.0. # R0278 Sigma Saint Louis MO),
containing protease inhibitor cocktail (Roche # 04693124001).
The samples were normalized for protein with ND-1000
(NanoDrop Technologies Inc., Wilmington DE). For western
blotting, 125 mg protein per lane were analyzed with primary
Figure 5. Metastasis in Lungs. Lungs showing metastatic areas from control (Figure 5A) and MMP1 silenced groups (Figure 5B) are shown.
Figure 5C shows histogram representing average percentage of total lung volume affected by metastasis at 5 weeks for control (54617.6%) and
MMP1 Silenced (36623.7%) groups. Difference in mean percentage area affected by metastasis is not significantly different, p=0.08.
doi:10.1371/journal.pone.0014250.g005
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HRP conjugated antibodies for 2 hours at room temperature.
Bands were detected with SuperSignal West Pico ECL detection
kit (# 34080, Pierce, Rockford IL) on UVP Biospectrum Digital
Imaging system (UVP Inc. Upland CA).
In Vitro Proliferation Assay
The in vitro cellular growth capacity was measured over 5 day
period. Each day a triplicate set was trypsinized, cells counted on
hematocytometer, and discarded. The logarithmic growth phase
(,between days 3 and 4) was used to determine growth speed in
culture (DX/DT) which expressed then as % difference relative to
control.
In Vitro Invasion Assay
The QCM
TM 96-well collagen-based cell invasion assay
Chemicon International (#ECM556) was used. After initial cell
number normalization, 4.0610
4 cells/well were seeded onto the
plate (9 parallels with 3 blank controls). The feeder wells contained
the same media +/- FBS (10%) to determine the effects of natural
metalloproteinase inhibitors, and incubated overnight. The
following day the plates were processed and measured with 480/
520 nm filter set on Berthold Mithras LB 970 plate reader.
Xenogenic Model of Metastasis
A xenogenic murine model of human sarcoma was used to
assess the effect on metastasis [14]. Four week old 70 SCID nu/nu
mice were divided into two groups of 35 mice each. One million
cells in a 10 micro liter volume were orthotopically implanted in
the left tibial metadiaphysis using a 27 gauge needle in two groups
of 35 animals each. Control group was implanted with GFP
+143B (V9) cell line and an MMP1 silenced group was implanted
with GFP + shRNA 143B (T6-4) cell line.
Sample size was calculated using the formula for one sided test.
The MMP1 silenced clone was expected to decrease the metastatic
potential of this cell line with a mean of 0.5 and range of 0-2.
Power 95%, alpha=0.01, beta=0.05. [14] Sample size was then
modified upward considering the rate of engraftment failure
known to occur. Institutional IACUC approval from University of
Miami (Institutional Animal Care and Use Committee University
of Miami) for this project was obtained (Approval Number 07-
251). We repeated the experiment using a second independent
Figure 6. Assessment of stablization of MMP Silencing. Figure 6A shows the Relative quantity (RQ) of MMP1 in the control and MMP1 silenced
clones isolated from mouse lungs at necropsy. MMP1 Silenced clone is 95% down-regulated as compared to control. Control =1.7260.17; MMP1
Silenced=0.0560.08. Figure 6B shows MMP1a production by peri-tumoral murine stromal tissue as assessed with laser capture microdissection and
QPCR.
doi:10.1371/journal.pone.0014250.g006
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of tumor cells. For that experiment we used 6 mice in each group
and sacrificed the animals at 2 and 5 weeks.
Di-I Staining
Di-I staining was carried out using the protocol described by Wen
et al. Briefly, fluorescent carbocyanine dye Di-I solution (1, 19-
Dioctadecyl-3, 3, 39,3 9-tetramethylindocarbo-cyanine perchlorate;
Catalog # 42364, Sigma-Aldrich, St. Louis, MO) and 4% parafor-
maldehyde (20 ml in 0.1 M phosphate buffer, pH 7.4). was injected
into the left ventricle. By the end of procedure, the paws, tail and the
ears turn pink indicating a successful systemic perfusion of Di-I [47].
Tumor Measurement
Local tumor volume was measured using the technique
described by Luu et al. [14]. Volume= (L) (W) (L+W) (0.2618),
where 0.2618 is the constant of proportionality.
An average of volume measurements by the two observers was
used as the final value.
Vascular Measurement
Local tumors were isolated after sacrificing the animal and
immediately embedded in OCT, snap frozen in liquid nitrogen and
stored. Tumor vascularity was measured using confocal microscopy
on a 50 micron thick frozen section using a 256/0.8 mA water
immersion lens on the Zeiss LSM 510/UV confocal microscope.
Five different areas, each having fluorescently labeled 143B cells
and Di-I stained blood vessels, were imaged and z-series for entire
thickness of tissue was determined. This procedure was repeated for
5 different cryosections and evaluated by two observers [48]. A 3D
reconstruction (LSM Image Browser) of each image was used to
calculate the Di-I stained area using the Metamorph Imaging
system 5.0
R (Universal Imaging Corp., Downingtown, PA.). A total
of 7 mice from each group were used for this estimation.
Pulmonary Burden
An ex-vivo estimation of pulmonary burden was made using
digital images of lung tissue and delineation with ImageJ
R v1.4
(NIH). Metastatic volume was determined using Metamorph
Imaging system 5.0
R (Universal Imaging Corp., Downingtown,
PA.). Metastatic area is presented as a percentage of total lung
volume. An ex-vivo estimation of pulmonary burden was also made
using the Xenogen IVIS (In-vivo imaging system). Region of
Interest measurements were made using the specific excitation and
emission wavelengths for the flurophore (GFP: FITC) used to label
the 143B cell line. Some, but not all of metastatic volume on visual
inspection corresponded with fluorescent area. Thus we used
visual delineation of metastatic area for the purpose of analysis.
Isolation of sarcoma cells from mouse tissue
Sarcoma cells were isolated out of the mouse primary tumor as
well as lung metastasis. The tumors were surgically excised and
homogenized with a surgical blade to small sizes that fit through
the 25 ml pipette, then transferred to a 50 ml conical tube and
incubated , three hours at 37uC with occasional gentle vortexing.
Following the incubation the mixture was filtered through Falcon
Cell Strainer (#352350 with 70 mm pore size Becton Dickinson
Labware, Franklin Lakes NJ) and 1 ml aliquots were dispersed into
p100 plates containing 143B culturing media completed with
puromycin selection. The isolated cells were re-grown in culture
and characterized for expression of MMP1.
Laser Micro-Dissection to assess the contribution of host
MMP1
Host MMP1 production was assessed to determine if tumor cell
MMP1 silencing was compensated for by surrounding stromal
cells. Murine stromal cells were dissected out from the 5 micron
thick frozen section of primary tumor using laser capture micro-
dissection technique. Arcturus
R Histo-Gene
R RNA Isolation kit
was used to isolate RNA according to manufacturer’s protocol.
Expression analysis (QPCR) on 2 samples from control group and
4 samples from silenced MMP1 silenced mice was carried out (ABI
Taqman Gene Expression Assays
R Mm473485_m1).
Statistical Analysis
Data are presented as means with standard error of mean (SEM).
Differences in means from the in vitro and in vivo experiments were
compared by using the Student’s t test. Differences were considered
significant at p,0.05. All statistical tests for analysis of outcomes were
two-tailed. Kaplan-Meier and Log Rank methods are used for analysis
of survival and differences were considered significant at p,0.05.
Supporting Information
Table S1 Data from the second experiment showing comparison
of second independent MMP1 silenced clone T6-7 and its
respective control group.
Found at: doi:10.1371/journal.pone.0014250.s001 (0.03 MB
XLS)
Video S1
Found at: doi:10.1371/journal.pone.0014250.s002 (0.51 MB
MP4)
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